Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 31
Filtrar
Más filtros











Intervalo de año de publicación
1.
Rev. neurol. (Ed. impr.) ; 33(8): 740-749, 16 oct., 2001.
Artículo en Es | IBECS | ID: ibc-27239

RESUMEN

Introducción. Numerosas observaciones sugieren que, aun cuando la principal expresión clínica en la enfermedad de Alzheimer (EA) es consecuencia de alteraciones en el cerebro, dicha enfermedad presenta múltiples alteraciones celulares y moleculares a nivel sistémico. Estas alteraciones no parecen tener consecuencias negativas fuera del sistema nervioso, pero, de producirse en el cerebro, podrían explicar las manifestaciones clínicas más sobresalientes como la pérdida de memoria. Desarrollo. Investigaciones recientes han demostrado experimentalmente que hay una conexión, directa o indirecta, entre alteraciones en los canales iónicos, proteincinasa C, homeostasis del calcio y el procesamiento del amiloide en células periféricas. Algunos estudios también presentan fenómenos similares en el cerebro, lo cual sugiere que los estudios en células extraneurales son relevantes. Conclusión. Dadas las dificultades y complicaciones asociadas con el uso de material post mortem, generalmente en estado muy avanzado o terminal, las células periféricas como los fibroblastos ofrecen un modelo adecuado para estudiar aspectos celulares de la fisiopatología de la EA (AU)


Asunto(s)
Humanos , Sistemas de Mensajero Secundario , Proteína Quinasa C , Señalización del Calcio , Enfermedad de Alzheimer , Homeostasis , Canales Iónicos , Eritrocitos , Fibroblastos , Telencéfalo
2.
Rev Neurol ; 33(8): 740-9, 2001.
Artículo en Español | MEDLINE | ID: mdl-11784972

RESUMEN

INTRODUCTION: Numerous observations indicate that, while the predominant clinical expression arises from brain pathology, Alzheimer s disease (AD) has systemic expression at the cellular and molecular levels. Although these alterations seem to be inconsequential outside the central nervous system, their parallel expression in the brain could be considered a plausible pathophysiological model and explain part of the clinical manifestations; in particular those related to memory loss. DEVELOPMENT: Recent research has provided experimental evidence of a direct or indirect linkage between alteration in ion channels, PKC, calcium homeostasis and amyloid processing in peripheral tissues. Some evidence also indicates similar phenomena in the brain, attesting to the relevance of the changes in non CNS cells. CONCLUSION: Considering the difficulties of using post mortem material to study dynamic and/or early event in mostly end stage, disease ridden tissues, peripheral cells such as fibroblasts offer a model to study cellular aspects of AD pathophysiology.


Asunto(s)
Enfermedad de Alzheimer/fisiopatología , Señalización del Calcio/fisiología , Canales Iónicos/metabolismo , Sistemas de Mensajero Secundario , Enfermedad de Alzheimer/diagnóstico , Enfermedad de Alzheimer/terapia , Encéfalo/fisiopatología , Eritrocitos/metabolismo , Fibroblastos/metabolismo , Homeostasis , Humanos , Proteína Quinasa C/metabolismo
3.
Brain Res Mol Brain Res ; 72(2): 205-13, 1999 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-10529479

RESUMEN

Several lines of evidence have implicated the amyloid precursor protein (APP) and its metabolic products as key players in Alzheimer's disease (AD) pathophysiology. The approximately 100 amino acid C-terminal fragment (C100) of APP has been shown to accumulate intracellularly in neurons expressing familial AD (FAD) mutants of APP and to cause neurodegeneration when expressed in transfected neuronal cells. Transgenic animals expressing this fragment in the brain also exhibit some neuropathological and behavioral AD-like deficits. Here, we present evidence that PC12 cells expressing the C100 fragment either via stable transfections or herpes simplex virus-mediated infections show alterations in calcium handling that are similar to those previously shown in fibroblasts from AD patients. This alteration in calcium homeostasis may contribute to the deleterious effects of C100 in PC12 cells. Our data also lend support for a pathophysiological role for C100 since it induces an alteration thought to play an important role in AD pathology.


Asunto(s)
Precursor de Proteína beta-Amiloide/fisiología , Bradiquinina/farmacología , Señalización del Calcio/efectos de los fármacos , Neuronas/efectos de los fármacos , Fragmentos de Péptidos/fisiología , Enfermedad de Alzheimer/metabolismo , Enfermedad de Alzheimer/patología , Precursor de Proteína beta-Amiloide/biosíntesis , Precursor de Proteína beta-Amiloide/genética , Animales , Canales de Calcio/metabolismo , Fibroblastos/metabolismo , Humanos , Receptores de Inositol 1,4,5-Trifosfato , Neuronas/metabolismo , Células PC12 , Fragmentos de Péptidos/biosíntesis , Fragmentos de Péptidos/genética , Ratas , Receptores Citoplasmáticos y Nucleares/metabolismo , Proteínas Recombinantes de Fusión/fisiología , Simplexvirus/genética , Transfección
4.
Neuroreport ; 10(5): 1035-40, 1999 Apr 06.
Artículo en Inglés | MEDLINE | ID: mdl-10321481

RESUMEN

Activation of protein kinase C is known to favor the alpha-secretase processing of the Alzheimer's disease (AD) amyloid precursor protein (APP), resulting in the generation of non-amyloidogenic soluble APP (sAPP). Consequently, the relative secretion of amyloidogenic Abeta1-40 and Abeta1-42(3) is reduced. This is particularly relevant since fibroblasts and other cells expressing APP and presenilin AD mutations secrete increased amounts of total Abeta and/or increased ratios of Abeta1-42(3)/Abeta1-40. Interestingly, PKC defects have been found in AD brain alpha and beta isoforms) and in fibroblasts (alpha isoform) from AD patients. Here, we use a novel PKC activator (benzolactam, BL) with improved selectivity for the alpha, beta and gamma isoforms to enhance sAPP secretion in fibroblasts from AD patients and in PC12 cells. Incubation (2 h) of AD fibroblasts with BL (1 and 10 microM) resulted in significant increases of sAPP secretion over basal levels. sAPP secretion in BL-treated AD cells was also slightly higher compared to control BL-treated fibroblasts, which only showed significant increases of sAPP secretion after treatment with 10 microM BL. Staurosporine (a PKC inhibitor) eliminated the effects of BL in both control and AD fibroblasts. BL and a related compound (LQ12) also caused an approximately 3-fold sAPP secretion in PC12 cells. The use of a novel and possibly non-tumorigenic PKC activator may prove useful to favor non-amyloidogenic APP processing and is, therefore, of potential therapeutic value.


Asunto(s)
Precursor de Proteína beta-Amiloide/metabolismo , Fibroblastos/metabolismo , Lactamas/farmacología , Células PC12/metabolismo , Enfermedad de Alzheimer/metabolismo , Enfermedad de Alzheimer/patología , Animales , Células Cultivadas , Activación Enzimática/efectos de los fármacos , Activación Enzimática/fisiología , Inhibidores Enzimáticos/farmacología , Humanos , Forbol 12,13-Dibutirato/farmacología , Proteína Quinasa C/antagonistas & inhibidores , Proteína Quinasa C/metabolismo , Ratas , Valores de Referencia , Solubilidad , Estaurosporina/farmacología
5.
Pharmacol Res ; 39(2): 81-8, 1999 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-10072697

RESUMEN

Calcium plays a pivotal role in mediating many important biological functions. The intracellular calcium concentration is tightly regulated by a variety of systems and mechanisms. Calcium is sequestered by various organelles such as mitochondria and/or endoplasmic reticulum and extruded across the plasma membrane by energy-dependent transport systems. Different Ca2+-binding proteins are also involved in these processes. Alterations in calcium homeostasis might be critically implicated in brain aging and in the neuropathology of Alzheimer's disease (AD). In fact, one of the postulated mechanisms of beta-amyloid toxicity seems to involve a Ca2+ dysregulation accompanied with enhanced vulnerability to excitotoxic stimuli. Although brain characteristic lesions-plaques and tangles-constitute the hallmarks of AD, accumulated evidence suggests the systemic feature of this disease. Therefore peripheral cell lines may represent a useful approach to explore the cellular pathophysiology of AD, including calcium alterations and associated phenomena.


Asunto(s)
Enfermedad de Alzheimer/metabolismo , Calcio/metabolismo , Enfermedad de Alzheimer/tratamiento farmacológico , Enfermedad de Alzheimer/patología , Células Sanguíneas/metabolismo , Línea Celular , Fibroblastos/metabolismo , Homeostasis , Humanos , Modelos Biológicos
6.
Mol Neurobiol ; 20(2-3): 93-109, 1999.
Artículo en Inglés | MEDLINE | ID: mdl-10966116

RESUMEN

Several lines of evidence indicate that Alzheimer's disease (AD) has systemic expression. Systemic changes are manifested as alterations in a number of molecular and cellular processes. Although, these alterations appear to have little or no consequence in peripheral systems, their parallel expression in the central nervous system (CNS) could account for the principal clinical manifestations of the disease. Recent research seems to indicate that alterations in ion channels, calcium homeostasis, and protein kinase C (PKC) can be linked and thereby constitute a model of pathophysiological relevance. Considering the difficulties of studying dynamic pathophysiological processes in the disease-ridden postmortem AD brain, peripheral tissues such as fibroblasts provide a suitable model to study molecular and cellular aspects of the disease.


Asunto(s)
Enfermedad de Alzheimer/fisiopatología , Canales Iónicos/fisiología , Nervios Periféricos/fisiopatología , Transducción de Señal/fisiología , Enfermedad de Alzheimer/patología , Encéfalo/patología , Encéfalo/fisiopatología , Calcio/metabolismo , Sistema Nervioso Central/fisiopatología , Humanos , Proteína Quinasa C/metabolismo
7.
Neurobiol Dis ; 5(3): 177-87, 1998 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-9848089

RESUMEN

Several alterations in fibroblasts of Alzheimer's disease (AD) patients have been described, including alterations in calcium regulation, protein kinase C (PKC), and potassium (K+) channels. Studies have also found reduced levels of the alpha isoform of PKC in brains and fibroblasts of AD patients. Since PKC is known to regulate ion channels, we studied K+ channel activity in fibroblasts from AD patients in the presence of (2S, 5S)-8-(1-decynyl)benzolactam (BL), a novel activator of PKC with improved selectivity for the alpha, beta, and gamma isoforms. We present evidence for restoration of normal K+ channel function, as measured by TEA-induced [Ca2+]i elevations, due to activation of PKC by BL. Representative patch-clamp data further substantiate the effect of BL on restoration of 113pS K+ channel activity. Immunoblotting analyses using an alpha-isozyme-specific PKC antibody confirm that BL-treated fibroblasts of AD patients show increased PKC activation. The present study suggests that PKC activator-based restoration of K+ channels may offer another approach to the investigation of AD pathophysiology, which in turn could lead to the development of a useful model for AD therapeutics.


Asunto(s)
Enfermedad de Alzheimer/metabolismo , Calcio/metabolismo , Proteína Quinasa C/metabolismo , Tetraetilamonio/farmacología , Carcinógenos/farmacología , Células Cultivadas , Dimetilsulfóxido/farmacología , Activación Enzimática/efectos de los fármacos , Excipientes/farmacología , Fibroblastos/química , Fibroblastos/citología , Fibroblastos/enzimología , Humanos , Immunoblotting , Lactamas/farmacología , Técnicas de Placa-Clamp , Forbol 12,13-Dibutirato/farmacología , Forboles/farmacología , Canales de Potasio/fisiología , Proteína Quinasa C/análisis
8.
Neurobiol Dis ; 5(1): 37-45, 1998 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-9702786

RESUMEN

We have previously identified alterations of K+ channel function, IP3-mediated calcium release, and Cp20 (a memory-associated GTP binding protein) in fibroblasts from Alzheimer's disease (AD) patients vs controls. Some of these alterations can be integrated into an index that distinguishes AD patients from controls with both high specificity and high sensitivity. We report here that alterations in IP3-mediated calcium responses are present in a large proportion of AD family members (i.e., individuals at high risk) before clinical symptoms of Alzheimer's disease are present. This was not the case if such members later "escaped" AD symptoms. This preclinical calcium signal correlate of later AD does not reflect, however, the presence of the PS1 familial AD gene.


Asunto(s)
Enfermedad de Alzheimer/genética , Enfermedad de Alzheimer/metabolismo , Calcio/metabolismo , Fibroblastos/metabolismo , Enfermedad de Alzheimer/patología , Bradiquinina/farmacología , Células Cultivadas , Fibroblastos/efectos de los fármacos , Humanos , Membranas Intracelulares/metabolismo , Persona de Mediana Edad , Valores de Referencia , Tetraetilamonio/farmacología
9.
FASEB J ; 12(1): 17-34, 1998 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-9438407

RESUMEN

Alterations in amyloid precursor protein (APP) metabolism, calcium regulation, oxidative metabolism, and transduction systems have been implicated in Alzheimer's disease (AD). Limitations to the use of postmortem brain for examining molecular mechanisms underscore the need to develop a human tissue model representative of the pathophysiological processes that characterize AD. The use of peripheral tissues, particularly of cultured skin fibroblasts derived from AD patients, could complement studies of autopsy samples and provide a useful tool with which to investigate such dynamic processes as signal transduction systems, ionic homeostasis, oxidative metabolism, and APP processing. Peripheral cells as well as body fluids (i.e., plasma and CSF) could also provide peripheral biological markers for the diagnosis of AD. The criteria required for a definite diagnosis of AD presently include clinical criteria in association with histopathologic evidence obtained from biopsy or autopsy. Thus, the use of peripheral markers as a diagnostic tool, either to predict or at least to confirm a diagnosis, may be of great importance.


Asunto(s)
Enfermedad de Alzheimer/diagnóstico , Biomarcadores/sangre , Biomarcadores/líquido cefalorraquídeo , Enfermedad de Alzheimer/genética , Enfermedad de Alzheimer/fisiopatología , Péptidos beta-Amiloides/sangre , Péptidos beta-Amiloides/líquido cefalorraquídeo , Precursor de Proteína beta-Amiloide/sangre , Precursor de Proteína beta-Amiloide/líquido cefalorraquídeo , Apolipoproteínas E/genética , Humanos , Sistemas Neurosecretores/fisiopatología , Proteínas tau/sangre , Proteínas tau/líquido cefalorraquídeo
10.
J Neurochem ; 68(1): 26-32, 1997 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-8978706

RESUMEN

Pigment epithelium-derived factor (PEDF) is a survival factor for cerebellar granule cells in culture. In the present study, we have investigated the ability of a recombinant form of PEDF (rPEDF) to protect against glutamate neurotoxicity. When rPEDF was added to cerebellar granule cell cultures 30 min before addition of 100 microM glutamate, glutamate-induced neuronal death was significantly reduced. The protective effect of rPEDF was dose-dependent in the range from 0.023 to 7.0 nM (1-500 ng/ml), with a half-maximal dose of 0.47 nM. An antibody to rPEDF blocked this protective effect. Measurement of intraneuronal free calcium levels demonstrated that rPEDF raised the basal calcium content. However, after the elevation of intracellular calcium in response to administration of glutamate, rPEDF reduced the plateau level seen in the presence of glutamate. These data show that PEDF can protect neurons against glutamate-induced neurotoxicity, possibly via a calcium-related pathway. The finding that only 30 min of preincubation is required for the neuroprotective effect, significantly faster than other known neurotrophic factors, suggests that PEDF may be useful clinically as a neuroprotective agent in the CNS.


Asunto(s)
Cerebelo/efectos de los fármacos , Proteínas del Ojo , Ácido Glutámico/farmacología , Factores de Crecimiento Nervioso , Neuronas/efectos de los fármacos , Fármacos Neuroprotectores/farmacología , Neurotoxinas/farmacología , Proteínas/farmacología , Serpinas/farmacología , Animales , Animales Recién Nacidos , Calcio/metabolismo , Células Cultivadas , Cerebelo/citología , Cerebelo/metabolismo , Sueros Inmunes/inmunología , Membranas Intracelulares/efectos de los fármacos , Membranas Intracelulares/metabolismo , Neuronas/metabolismo , Proteínas/inmunología , Ratas , Ratas Sprague-Dawley , Proteínas Recombinantes , Serpinas/inmunología
11.
Neurobiol Aging ; 17(4): 549-55, 1996.
Artículo en Inglés | MEDLINE | ID: mdl-8832629

RESUMEN

We have previously identified alterations of K+ channel function, IP3-mediated calcium release, and Cp20 (a memory-associated GTP binding protein) in fibroblasts from AD patients vs. controls. In the present study we introduce a scoring system based on these response alterations that integrates two or more alterations (and their degree) in AD vs. control fibroblasts. This scoring system generates an index that distinguishes AD patients from controls with both high specificity and sensitivity. We also show that low doses of bradykinin elicit intracellular calcium release almost exclusively in AD cell lines in an all or none fashion that provide a clear measurement of enhanced IP3-mediated function in AD vs. controls.


Asunto(s)
Enfermedad de Alzheimer/metabolismo , Calcio/metabolismo , Fibroblastos/metabolismo , Anciano , Anciano de 80 o más Años , Bradiquinina/farmacología , Células Cultivadas , Femenino , Humanos , Masculino , Persona de Mediana Edad
12.
Life Sci ; 59(5-6): 491-8, 1996.
Artículo en Inglés | MEDLINE | ID: mdl-8761337

RESUMEN

It has been shown that K+ channels, Cp20 (a 20kD GTP-binding protein), and intracellular calcium release, play a key role in associative memory storage. These same elements have been shown to be altered in fibroblasts from Alzheimer's Disease (AD) patients. In addition, it has been shown that PKC, also implicated in memory storage and closely related to the above mentioned components, is also altered in AD fibroblasts. Moreover, beta-amyloid was capable of inducing an AD-like phenotype for K+ channels and Cp20 in otherwise normal fibroblasts, providing additional evidence for the potential involvement of these components in AD and suggesting a possible pathological consequence of soluble beta-amyloid elevation in AD. Preliminary evidence shows that comparable changes in potassium channel function are also present in human olfactory neuroblasts from AD patients. These results indicate that the observed changes not only occur in peripheral tissues such as fibroblasts, but also in neural tissue, the primary site of AD pathology.


Asunto(s)
Enfermedad de Alzheimer/metabolismo , Péptidos beta-Amiloides/fisiología , Proteínas de Unión al GTP Monoméricas , Neuronas/metabolismo , Enfermedad de Alzheimer/genética , Enfermedad de Alzheimer/patología , Péptidos beta-Amiloides/metabolismo , Fibroblastos/metabolismo , Proteínas de Unión al GTP/metabolismo , Humanos , Neuronas/patología , Fenotipo , Fosfoproteínas/metabolismo , Canales de Potasio/metabolismo
13.
Neuroreport ; 6(10): 1429-33, 1995 Jul 10.
Artículo en Inglés | MEDLINE | ID: mdl-7488741

RESUMEN

The beta-amyloid (a beta) peptide is a neurotoxic peptide that accumulates in the brains of Alzheimer patients, but is also present in body fluids at subnanomolar levels. The potential effects of these low levels of a beta are unclear. We have recently shown that physiologic levels of a beta increase tyrosine phosphorylation and induce increases in cytosolic calcium. The basement membrane mixture, Matrigel, is required for observation of the a beta-induced calcium response. We now show that transforming growth factor beta (TGF beta) is the active component in Matrigel eliciting the a beta/calcium response. The response to the type of TGF beta varies depending on the cell type with TGF beta 1 eliciting a beta responsiveness in olfactory neuroblasts, and TGF beta 2 eliciting a beta responsiveness in PC12 cells.


Asunto(s)
Péptidos beta-Amiloides/farmacología , Calcio/metabolismo , Neuronas/metabolismo , Neurotoxinas/farmacología , Factor de Crecimiento Transformador beta/farmacología , Animales , Proteínas de la Matriz Extracelular/metabolismo , Neuronas/efectos de los fármacos , Nervio Olfatorio/citología , Nervio Olfatorio/efectos de los fármacos , Nervio Olfatorio/metabolismo , Células PC12 , Ratas , Transducción de Señal/efectos de los fármacos
14.
Brain Res ; 681(1-2): 65-74, 1995 May 29.
Artículo en Inglés | MEDLINE | ID: mdl-7552293

RESUMEN

The a beta peptide is a neurotoxic peptide that accumulates in the brains of Alzheimer patients, but is also present in body fluids at subnanomolar levels. The potential effects of these low levels of a beta are unclear. We now show that one such action is to increase tyrosine phosphorylation in PC12 cells and olfactory neuroblasts. Application of a beta 25-35 or a beta 1-40 induces a dose-dependent increase in the tyrosine phosphorylation in both whole cells and in vitro. The increase in tyrosine phosphorylation is both rapid and sensitive, being stimulated by picomolar doses of a beta and occurring within 1 min of application. Calcium imaging experiments provide further support for the role of tyrosine phosphorylation in the action of a beta. While a beta does not alter calcium metabolism under basal conditions, the addition of a beta induces a rapid increase in cytoplasmic calcium in olfactory neuroblasts that have been treated with the tyrosine phosphatase inhibitor, sodium orthovanadate or in PC12 cells treated with nerve growth factor. These responses could be blocked by the tyrosine kinase inhibitor, herbimycin. These calcium responses displayed an obligate requirement for the presence of matrix proteins. The identification of a rapid, sensitive assay for the action of a beta may facilitate investigations of its mechanism of action.


Asunto(s)
Péptidos beta-Amiloides/farmacología , Calcio/metabolismo , Citosol/metabolismo , Tirosina/metabolismo , Animales , Proteínas Quinasas Dependientes de Calcio-Calmodulina/metabolismo , Citosol/efectos de los fármacos , Colorantes Fluorescentes , Fura-2 , Immunoblotting , Cinética , Neuronas/efectos de los fármacos , Neuronas/metabolismo , Bulbo Olfatorio/citología , Bulbo Olfatorio/efectos de los fármacos , Bulbo Olfatorio/metabolismo , Células PC12 , Fosforilación , Pruebas de Precipitina , Ratas
15.
Proc Natl Acad Sci U S A ; 92(7): 3060-4, 1995 Mar 28.
Artículo en Inglés | MEDLINE | ID: mdl-7708775

RESUMEN

The two proteins most consistently identified in the brains of patients with Alzheimer disease (AD) have been beta-amyloid and tau, whose roles in the physiology or pathophysiology of brain cells are not fully understood. To identify other protein(s) involved in AD that have been implicated in physiological contexts, we undertook to analyze a specific memory-associated protein, Cp20, in fibroblasts from AD and control donors. Cp20, a GTP-binding protein that is a member of the ADP-ribosylation factor family, was significantly decreased in fibroblasts from AD patients. Normal control fibroblasts exposed to 10 nM beta-amyloid, the same concentration that induced AD-like K+ changes in control fibroblasts, showed a similar decrease in Cp20. Since it has been previously demonstrated that Cp20 is a potent regulator of K+ channels, these findings suggest that changes in this memory-associated protein may explain previously observed differences in AD K+ channels and suggest a pathophysiologic involvement linked to soluble beta-amyloid metabolism that could contribute to the characteristic memory loss of AD.


Asunto(s)
Péptidos beta-Amiloides/farmacología , Proteínas de Unión al GTP/metabolismo , Memoria , Piel/metabolismo , Enfermedad de Alzheimer/metabolismo , Animales , Anticuerpos Monoclonales , Western Blotting , Línea Celular , Células Cultivadas , Electroforesis en Gel de Poliacrilamida , Fibroblastos/metabolismo , Humanos , Ratones/inmunología , Potasio/metabolismo , Canales de Potasio/fisiología
17.
Science ; 264(5156): 276-9, 1994 Apr 08.
Artículo en Inglés | MEDLINE | ID: mdl-8146663

RESUMEN

Although beta-amyloid is the main constituent of neurite plaques and may play a role in the pathophysiology of Alzheimer's disease, mechanisms by which soluble beta-amyloid might produce early symptoms such as memory loss before diffuse plaque deposition have not been implicated. Treatment of fibroblasts with beta-amyloid (10 nM) induced the same potassium channel dysfunction previously shown to occur specifically in fibroblasts from patients with Alzheimer's disease--namely, the absence of a 113-picosiemen potassium channel. A tetraethylammonium-induced increase of intracellular concentrations of calcium, [Ca2+]i, a response that depends on functional 113-picosiemen potassium channels, was also eliminated or markedly reduced by 10 nM beta-amyloid. Increased [Ca2+]i induced by high concentrations of extracellular potassium and 166-picosiemen potassium channels were unaffected by 10 nM beta-amyloid. In Alzheimer's disease, then, beta-amyloid might alter potassium channels and thus impair neuronal function to produce symptoms such as memory loss by a means other than plaque formation.


Asunto(s)
Enfermedad de Alzheimer/metabolismo , Péptidos beta-Amiloides/farmacología , Fibroblastos/efectos de los fármacos , Canales de Potasio/efectos de los fármacos , Bombesina/farmacología , Calcio/metabolismo , Línea Celular , Células Cultivadas , Dimetilsulfóxido/farmacología , Femenino , Fibroblastos/metabolismo , Humanos , Masculino , Fenotipo , Bloqueadores de los Canales de Potasio , Canales de Potasio/metabolismo , Cloruro de Potasio/farmacología , Solubilidad , Tetraetilamonio , Compuestos de Tetraetilamonio/farmacología
18.
Proc Natl Acad Sci U S A ; 91(2): 534-8, 1994 Jan 18.
Artículo en Inglés | MEDLINE | ID: mdl-8290560

RESUMEN

The recent demonstration of K+ channel dysfunction in fibroblasts from Alzheimer disease (AD) patients and past observations of Ca(2+)-mediated K+ channel modulation during memory storage suggested that AD, which is characterized by memory loss and other cognitive deficits, might also involve dysfunction of intracellular Ca2+ mobilization. Bombesin-induced Ca2+ release, which is inositol trisphosphate-mediated, is shown here to be greatly enhanced in AD fibroblasts compared with fibroblasts from control groups. Bradykinin, another activator of phospholipase C, elicits similar enhancement of Ca2+ signaling in AD fibroblasts. By contrast, thapsigargin, an agent that releases Ca2+ by direct action on the endoplasmic reticulum, produced no differences in Ca2+ increase between AD and control fibroblasts. Depolarization-induced Ca2+ influx data previously demonstrated the absence of between-group differences of Ca2+ pumping and/or buffering. There was no correlation between the number of passages in tissue culture and the observed Ca2+ responses. Furthermore, cells of all groups were seeded and analyzed at the same densities. Radioligand binding experiments indicated that the number and affinity of bombesin receptors cannot explain the observed differences. These and previous observations suggest that the differences in bombesin and bradykinin responses in fibroblasts and perhaps other cell types are likely to be due to alteration of inositol trisphosphate-mediated release of intracellular Ca2+.


Asunto(s)
Enfermedad de Alzheimer/metabolismo , Calcio/metabolismo , Fibroblastos/metabolismo , Adulto , Anciano , Bombesina/farmacología , Bradiquinina/farmacología , Línea Celular , Femenino , Fibroblastos/efectos de los fármacos , Humanos , Líquido Intracelular/metabolismo , Masculino , Persona de Mediana Edad , Modelos Biológicos , Canales de Potasio/metabolismo , Receptores de Bombesina/metabolismo , Transducción de Señal , Fosfolipasas de Tipo C/metabolismo
19.
J Neurochem ; 61(6): 2303-10, 1993 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-8245981

RESUMEN

We investigated the effects of lithium on alterations in the amount and distribution of protein kinase C (PKC) in discrete areas of rat brain by using [3H]phorbol 12,13-dibutyrate quantitative autoradiography as well as western blotting. Chronic administration of lithium resulted in a significant decrease in membrane-associated PKC in several hippocampal structures, most notably the subiculum and the CA1 region. In contrast, only modest changes in [3H]phorbol 12,13-dibutyrate binding were observed in the various other cortical and subcortical structures examined. Immunoblotting using monoclonal anti-PKC antibodies revealed an isozyme-specific 30% decrease in hippocampal membrane-associated PKC alpha, in the absence of any changes in the labeling of either the beta (I/II) or gamma isozymes. These changes were observed only after chronic (4 week) treatment with lithium, and not after acute (5 days) treatment, suggesting potential clinical relevance. Given the critical role of PKC in regulating neuronal signal transduction, lithium's effects on PKC in the limbic system represent an attractive molecular mechanism for its efficacy in treating both poles of manic-depressive illness. In addition, the decreased hippocampal membrane-associated PKC observed in the present study offers a possible explanation for lithium-induced memory impairment.


Asunto(s)
Encéfalo/enzimología , Hipocampo/enzimología , Isoenzimas/metabolismo , Carbonato de Litio/farmacología , Proteína Quinasa C/metabolismo , Animales , Autorradiografía , Hipocampo/efectos de los fármacos , Masculino , Especificidad de Órganos , Forbol 12,13-Dibutirato/metabolismo , Tractos Piramidales/enzimología , Ratas , Ratas Sprague-Dawley , Tritio
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA